Michael D. Grisham

Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream.

Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream.

Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream.

Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream.

Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream.

Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream.

Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream.